Acurx Pharma Q1 net loss $4.4M; Phase 2b data positive, FDA agrees on Phase 3 plan

Acurx Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.28

Net loss of $4.4M ($0.28/diluted share) vs $2.9M loss in Q1 2023; R&D expenses $1.6M, G&A $2.8M.
Cash $8.9M at March 31, 2024; raised ~$4.4M gross via ATM sale of 1,121,793 shares in Q1.
Phase 2b ibezapolstat results: 94% eradication of fecal C. difficile at Day 3 vs 71% for vancomycin; preserved gut microbiome.
End of Phase 2 meeting with FDA in April 2024; agreement reached on Phase 3 program and NDA pathway.
EMA approved SME designation for Acurx, granting fee reductions and support for European marketing authorization.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Acurx Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: net income $4.4 million or $0.28 per diluted share, EPS $0.28 per diluted share.

Period: the first quarter ended March 31, 2024
Net income: $4.4 million or $0.28 per diluted share
EPS: $0.28 per diluted share
Result: reported results

Exact text from the filing

The Company reported a net loss of $4.4 million or $0.28 per diluted share for the three months ended March 31, 2024

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Acurx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-061579

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.